Stock 9SO SOLASIA PHARMA K.K.
Add to a list
To use this feature you must be a member
Log inSign up

Company Solasia Pharma K.K. Deutsche Boerse AG

Equities

9SO

JP3436500007

Pharmaceuticals

Delayed Deutsche Boerse AG
Other stock markets
 03:49:44 2024-04-30 pm EDT 		5-day change 1st Jan Change
0.135 EUR -0.74% Intraday chart for Solasia Pharma K.K. +2.27% -49.63%
Mar. 04 Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited CI
Feb. 16 Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond CI

Business Summary

Solasia Pharma K.K. is a Japan-based pharmaceutical company. The Company is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. It focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The Company's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).

Number of employees: 24

Sales per Business

JPY in Million2022Weight2023Weight Delta
Pharmaceuticals
100.0 %
1,092 100.0 % 617 100.0 % -43.50%

Sales per region

JPY in Million2022Weight2023Weight Delta
China and Other
86.9 %
768 70.4 % 536 86.9 % -30.21%
Japan
13.1 %
323 29.6 % 81 13.1 % -74.92%

Managers

Managers TitleAgeSince
Yoshihiro Arai CEO
 Chief Executive Officer 63 07-08-31
Koji Shinozaki FOU
 Founder - 06-11-30
Toshio Miyashita DFI
 Director of Finance/CFO 56 13-12-31
Yasumitsu Shimada IRC
 Investor Relations Contact - -
Yasuaki Manabe SAM
 Sales & Marketing - -

Members of the board

Members of the board TitleAgeSince
Yiu Kwan Lau BRD
 Director/Board Member 69 14-11-30
Yoshihiro Arai CEO
 Chief Executive Officer 63 07-08-31
Toshio Miyashita DFI
 Director of Finance/CFO 56 13-12-31
Norikazu Eiki BRD
 Director/Board Member 76 16-03-31
Jiro Mizukawa BRD
 Director/Board Member 71 20-03-29
Stanley Lau BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 192,994,010 158,362,712 ( 82.06 %) 430,910 ( 0.2233 %) 82.06 %

Shareholders

NameEquities%Valuation
NIPPON KAYAKU CO., LTD.
6.711 %
12,000,000 6.711 % 3 M €
Maruho Co., Ltd.
6.332 %
11,324,000 6.332 % 2 M €
Shinichi Asai
0.9466 %
1,692,700 0.9466 % 369 076 €
Hitoshi Imamura
0.6475 %
1,157,900 0.6475 % 252 469 €
Yoshihiro Arai
0.6456 %
1,154,545 0.6456 % 251 737 €
Toshio Miyashita
0.2781 %
497,300 0.2781 % 108 431 €
Solasia Pharma Employee Incentive Plan
0.2410 %
430,900 0.2410 % 93 953 €
ITOCHU CORPORATION
0.1012 %
180,943 0.1012 % 39 453 €
Simplex Asset Management Co., Ltd.
0.000000 %
0 0.000000 % - €

Company contact information

Solasia Pharma KK

Sumitomo Fudosan Shiba-Koen Tower 4F 2-11-1 Shiba-koen

105-0011, Tokyo

+81 3 5843 8045

http://www.solasia.co.jp
address Solasia Pharma K.K.(9SO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Solasia Pharma K.K.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
26 JPY
Average target price
100 JPY
Spread / Average Target
+284.62%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-4.24% 86.85B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.16B
BIOGEN INC. Stock Biogen Inc.
-16.98% 31.28B
UCB Stock UCB
+57.86% 25.27B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.24% 15.33B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
INCYTE CORPORATION Stock Incyte Corporation
-17.10% 11.69B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.89% 8.83B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 4597 Stock
  4. 9SO Stock
  5. Company Solasia Pharma K.K.